Literature DB >> 31494449

Generation of three induced pluripotent stem cell lines from an isolated inherited retinal dystrophy patient with RCBTB1 frameshifting mutations.

Zhiqin Huang1, Dan Zhang2, Shang-Chih Chen2, Jennifer A Thompson3, Terri McLaren4, Tina Lamey4, John N De Roach4, Samuel McLenachan5, Fred K Chen6.   

Abstract

Variants in RCBTB1 have been implicated in inherited retinal disease (IRD). Here, we generated induced pluripotent stem cells (iPSCs) from a 45-year-old female IRD patient harbouring compound heterozygous mutations in the RCBTB1 gene. Episomal plasmids containing OCT4, SOX2, KLF4, MYCL, LIN28, shRNA for TP53 and mir302/367 microRNA were employed to conduct the reprogramming of primary dermal fibroblasts. These iPSC lines provide a useful model for further investigations on the pathophysiological role of mutations in the RCBTB1 gene in IRD.
Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31494449     DOI: 10.1016/j.scr.2019.101549

Source DB:  PubMed          Journal:  Stem Cell Res        ISSN: 1873-5061            Impact factor:   2.020


  2 in total

1.  Novel RCBTB1 variants causing later-onset non-syndromic retinal dystrophy with macular chorioretinal atrophy.

Authors:  Andrew J Catomeris; Brian G Ballios; Riccardo Sangermano; Naomi E Wagner; Jason I Comander; Eric A Pierce; Emily M Place; Kinga M Bujakowska; Rachel M Huckfeldt
Journal:  Ophthalmic Genet       Date:  2022-01-20       Impact factor: 1.274

2.  Gene replacement therapy restores RCBTB1 expression and cilium length in patient-derived retinal pigment epithelium.

Authors:  Zhiqin Huang; Dan Zhang; Shang-Chih Chen; Luke Jennings; Livia S Carvalho; Sue Fletcher; Fred K Chen; Samuel McLenachan
Journal:  J Cell Mol Med       Date:  2021-10-07       Impact factor: 5.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.